Another small step forward for Lokelma with UK reimbursement easing

The British pricing and reimbursement agency has updated its guidance for AstraZeneca’s (LSE: AZN) Lokelma (sodium zirconium cyclosilicate), broadening access to the therapy.

The drug is indicated for the treatment of adults with hyperkalemia, a condition of elevated potassium levels in the blood which can cause cardiac arrest and death.

The new guidance, which follows a change to the commercial arrangements in place, means that Lokelma is no longer restricted to hospital use only, and can be offered by primary care providers.